Case Reports

Significant response to lacosamide in a patient with severe chemotherapy-induced peripheral neuropathy


 

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting toxicity of potentially curative cancer therapy regimens. Cisplatin is the class of chemotherapy agent that has a broad spectrum of activity against several solid tumors, but it induces sensory neuropathy of upper and lower extremities. Cisplatin-induced peripheral neuropathy is usually in a “gloves and socks” distribution that can persist for months or years after completion of chemotherapy treatment. If the pain is severe, it affects the patient’s long-term quality of life and can potentially result in chemotherapy dose reduction or treatment discontinuation.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Precision medicine in the making
MDedge Hematology and Oncology
Cost of palliative external beam radiotherapy (EBRT) use for bone metastases secondary to prostate cancer
MDedge Hematology and Oncology
Pelvic pleomorphic rhabdomyosarcoma presenting as oliguria in a 61-year-old woman
MDedge Hematology and Oncology
Circulating tumor cells and LDH level provide surrogate for survival in advanced prostate cancer
MDedge Hematology and Oncology
New drugs signal promise for rare leukemia, prostate cancer
MDedge Hematology and Oncology
Cixutumumab provided no boost to androgen deprivation therapy
MDedge Hematology and Oncology
Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting
MDedge Hematology and Oncology
AACR: Biomarker of response to olaparib found
MDedge Hematology and Oncology
Androgen deprivation linked to cognitive impairment
MDedge Hematology and Oncology
Symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment
MDedge Hematology and Oncology